RADIOIMMUNOASSAY/BIOMARKERS CORE

放射免疫测定/生物标志物核心：主管-B。狼 我们建议继续为本地具规模的机构提供生物标记物及放射免疫分析服务， 一组研究人员。分析服务已被证明是必不可少的，目前的研究在DERC/宾夕法尼亚大学 糖尿病中心，它也将是未来运营和发展的一个组成部分， 中心 在布莱恩·沃尔夫、穆雷达克·赖利和石楠柯林斯博士的领导下，内核已经进化 从过去主要专注于大鼠和人胰岛素、胰高血糖素和C肽的设施， 多样化、高容量和具有成本效益的服务。超过50种不同的糖尿病和内分泌相关疾病 可以测定标记物。我们认为，进行大量的放射免疫测定， 在一个中央核心设施，而不是在整个大学分散的地点ELISA代表 设备的显著总体节省，并且还提供了具有更好质量控制的结果。 分析的增加反映了糖尿病研究扩展到炎症领域， 肥胖和宾夕法尼亚科学界对新陈代谢的兴趣增加。平行于该 随着检测数量的增加，核心也经历了更多的研究人员使用其服务（25名Pis， 2001年为37名，2005年为37名）。我们利用收费系统来收回分析的成本， 我们的收费由每个样本1元至8元不等，是所有DERC/DRTC中收费最低的。 放射免疫分析/生物标志物核心在下一个周期的愿景包括（1） 合并现有服务，（2）向现有和新的调查员提供新服务，（3） 发展信息基础设施，以有效地提供服务，以及（4）主动参与 与宾夕法尼亚大学研究界进行外联，以提高效率、分担费用和增加用户 生物标志物核心服务

RADIOIMMUNOASSAY/BIOMARKERS CORE: Director-B. Wolf We propose to continue offering Biomarker and Radioimmunoassay services to our sizable local group of researchers. The assay service has proven essential for current research in the DERC/Penn Diabetes Center and it will also be an integral part of the future operation and development of the Center. Under the leadership of Drs. Bryan Wolf, Muredach Reilly and Heather Collins, the Core has evolved from a facility that used to be focused mainly on rat and human insulin, glucagon and C-peptide to a diverse, high-volume and cost-effective service. Over 50 different diabetes and endocrinology-related markers can be assayed. We believe that performing a large number of radioimmunoassays and ELISAs in a central core facility rather than in scattered locations throughout the University represents a significant overall savings in equipment and also provides results with better quality control. The increase in assays reflects the expansion of diabetes research into the areas of inflammation and obesity and the increased interest in metabolism by the Penn scientific community. Parallel to this increase in assays, the Core has also experienced more investigators using its services (25 Pis in 2001 versus 37 Pis in 2005). We utilize a charge-back system to recover the cost of the assays and our charges vary from $1 to $8 per sample, which are among the lowest of all DERC/DRTCs. The vision for the Radioimmunoassay/Biomarkers Core over the next cycle includes (1) consolidation of existing services, (2) delivery of new services to existing and new investigators, (3) development of informatic infrastructure for efficient delivery of service, and (4) to proactively engage in outreach to the PENN research community to enhance efficiency, cost-sharing and increase users of Biomarker Core services.